Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.


Amid persistent macroeconomic challenges and impending patent cliffs, key players in the life science industry are increasingly seeking strategic partnerships with Chinese biopharma firms to gain access to innovative products and technologies. These alliances may offer a cost-effective way for international companies to replenish pipelines and secure their future growth as well as provide Chinese firms with a revenue boost and global recognition.
Notably, 61 China-to-International partnering deals were announced in H1 2025, with 37 of those involving a US company. The aggregate total deal spend on Chinese-originated assets has also soared in recent years, reaching US$48.5 billion in the first half of 2025 compared to US$44.8 billion in the whole year of 2024.
Explore how China's biopharma sector is reshaping global dealmaking. By downloading the full article, you'll gain insights into:
Download the article for the latest deal breakdowns, emerging trends, and strategic perspectives shaping the next wave of global pharma innovation.
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.